Online Inquiry

RDC Binding Analysis Service

Radiopharmaceuticals are rapidly evolving, and RDC (Radionuclide Drug Conjugate), as a member of them, are receiving lots of attention. An in-depth understanding of binding interactions between targeted molecules and ligand is crucial to elucidating binding mechanisms and stability during the RDC development.

Rdcthera have set up an excellent RDC analysis platform and standard procedures to provide cost-effective and customized complement radioligand binding analysis service for global clients.

Fig.1 Diagram of ELISA.

Overview of Receptor/Ligand Affinity

The targeting molecule in RDC, working as a vector, is one kind of ligand, that enables identification and binding with the specific receptors expressed on the targeted cell when RDC is infused into the bloodstream. The radioactive isotope in the RDC is effectively used in diagnostic imaging and cancer treatment.

Binding affinity refers to the strength of interaction between a receptor and a ligand. The higher the affinity between the targeted receptor and the radioligand, the more radioactive beam is released at the binding site to conduct clinical effects. Radioligand binding analysis service is an essential method to measure the interaction between receptors and different kinds of RDC, which provides crucial information and key properties for RDC development.

Fig.2 Dividing Line.

Our Service

The binding analysis approaches have evolved for decades and include a wide range of highly sensitive binding assays. Rdcthera have top-notched platforms to characterize the affinity of your RDC product, as well as professional machine learning methods to calculate the affinity score of your RDC product with a mathematical model.

  • Binding Affinity Analysis for All Three Kinds of RDC.
  • Antibody-Based RDC Binding Analysis
    Rdcthera offers a high throughput, sensitive, flexible, and rapid solution for antibody-based RDC-receptor binding analysis
  • Small Molecule-Based RDC Binding Analysis
    Determining and evaluating the affinity of small molecule-based RDC binding to a therapeutic target is an important property during RDC development and lead optimization. Rdcthera offer professional binding analysis for your small molecule-based RDC.
  • Peptide-Based RDC Binding Analysis
    Rdcthera has advanced platforms to characterize peptide-based RDC binding ability.
  • Three Methods of Radioligand Binding Assay
  • The competitive radioligand binding assay is used to determine the relative affinities of RDC for binding to a targeted receptor site in a cancer cell membrane. Our standard analysis procedure is performed by incubating a gradient of concentrations of the unlabeled control ligand with a fixed concentration of radioligand and measuring the IC50 (nM) with duplicate determinations to analyze the affinity ability.
  • The saturation radioligand binding assay is used to determine the number of binding sites in the tissue or cultured cells, and the dissociation constant. The standard procedure is performed by gradient increasing concentrations of the RDC to directly measure the level of receptor binding with duplicate determinations.
  • The kinetic radioligand binding assay is used to determine the association and dissociation rates of RDC from a receptor with duplicate determinations.

Project Workflow

Project Workflow.

Why Choose Us

Why Choose Us

Rdcthera adhere strictly to our core technology and our scientists are all experienced and professional and undertake standard or custom analysis service on your samples according to your demand. Please contact us for more information.

For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy